Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Enlivex Therapeutics (ENLV) to $13 from $7 and keeps a Buy rating on the shares. The cites the company’s entry into the prediction markets via its digital asset treasury strategy for that target boost. Enlivex utilized the majority of the proceeds from its private investment in public equity to implement the first RAIN prediction markets token treasury strategy, the analyst tells investors in a research note.